DXS International plc Trading Statement
May 28 2021 - 1:00AM
UK Regulatory
TIDMDXSP
DXS INTERNATIONAL PLC
(AQSE: DXSP)
Trading Update May 2021
DXS International plc ("DXS", the "Company"), the AQSE quoted clinical
decision support developer and supplier of clinical decision support
systems, is pleased to provide shareholders with the following trading
update.
For the twelve months ending April 2021, we are pleased to announce that
we have been able to achieve a similar profit to the year ending 2020
with turnover marginally improved for the same period. This was due to a
slight increase in existing sales from both the NHS and the
Pharmaceutical industry and initial revenue for the Hypertension
program. Last financial year to 30 April 2020, turnover was GBP3.28m and
net profit was GBP429k.
Although launching our new solutions as originally intended has been
severely hampered due to the COVID pandemic occupying GP's focus, we
have managed to continue with our pilots, albeit at a slower pace than
originally envisaged. As Covid related pressure on GPs subsides we
anticipate that we will be able to progress pilots at a more normal
pace.
The feedback obtained so far from the pilots has been excellent with
positives being highlighted and constructive criticism enabling our
teams to continue with fixes and enhancements.
Our process of applying for NHS GPIT Futures accreditation is complete
with all standards having been approved and we anticipate formal
accreditation being awarded imminently. This means that Clinical
Commissioning Groups (CCG's) will be able to procure our ExpertCare
hypertension solution via a central NHS fund.
Regarding our international activities, we were sadly not selected for
phase II of the European Union's Horizon Research and Development
programme. Although receiving much positive feedback for the quality of
our submission, the programme has decided to take forward participants
based in the EU requiring less EU investment. However, we have
benefitted hugely from being selected for phase I which provided grant
funding to develop our understanding of the challenges across Europe for
dealing with Hypertension. This has enabled us to create a detailed
blueprint for adapting our Hypertension solution to meet these needs and
address new markets.
David Immelman, Chief Executive of DXS said:
"While there are early signs of the healthcare market beginning to
normalise, GPs and Primary Care staff remain pressured, particularly
while facing significant backlogs built up during the past 18 months.
This however has presented an opportunity which is evident by the keen
interest being shown in our CompleteCare cancer toolkit which can
potentially assist practices expedite cancer treatment backlogs.
Although frustrated by delays, our sales and marketing team remain
focused and we continue to persevere with our sales and marketing
efforts both in the UK and abroad."
The Directors of DXS International plc accept responsibility for this
announcement
Enquiries:
David Immelman (Chief Executive) 01252 719800
DXS International plc david@dxs-systems.com
https://www.dxs-systems.co.uk
Corporate Advisor
City & Merchant
David Papworth 020 7101 7676
Corporate Broker
Hybridan LLP
Claire Louise Noyce 020 3764 2341
Notes to Editors
About DXS:
DXS International presents up to date treatment guidelines and
recommendations, from Clinical Commissioning Groups and other trusted
NHS sources, to doctors, nurses and pharmacists in their workflow and
during the patient consultation. This effective clinical decision
support ultimately translates to improved healthcare outcomes delivered
more cost effectively and which should significantly contribute towards
the NHS achieving its projected efficiency savings.
(END) Dow Jones Newswires
May 28, 2021 02:00 ET (06:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DXS (AQSE:DXSP)
Historical Stock Chart
From May 2024 to Jun 2024
DXS (AQSE:DXSP)
Historical Stock Chart
From Jun 2023 to Jun 2024